CD30: expression and function in health and disease
- PMID: 9826579
- DOI: 10.1006/smim.1998.0156
CD30: expression and function in health and disease
Abstract
CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) established these proteins as members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfamilies, respectively. Expression of CD30 is mostly restricted to virus-infected lymphocytes, neoplasms of lymphoid origin and a subset of activated T cells which produce Th2-type cytokines. The ligand is present on activated T cells, resting B cells, granulocytes, and the medulla of the thymus (epithelial cells and Hassal's corpuscles) as well as in various leukemia cells. The biological function of CD30 is pleiotropic but has come to be understood in the context of co-stimulatory signals. Signal transduction of CD30 utilizes signal transducers, TNFR-associated factors (TRAF1, 2, 3 and 5), which are shared by other TNFR family members. Mechanisms of signal transduction leading to diverse biological functions remain to be elucidated.
Copyright 1998 Academic Press
Similar articles
-
Expression and function of CD30 on T lymphocytes.Arch Immunol Ther Exp (Warsz). 1999;47(4):217-21. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10483869 Review.
-
TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.Mol Immunol. 2009 Aug;46(13):2441-8. doi: 10.1016/j.molimm.2009.05.178. Epub 2009 Jun 21. Mol Immunol. 2009. PMID: 19540595
-
Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94. Leukemia. 1994. PMID: 7528856
-
mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.Leuk Res. 2006 Mar;30(3):343-8. doi: 10.1016/j.leukres.2005.08.010. Epub 2005 Sep 29. Leuk Res. 2006. PMID: 16198418
-
CD30 in normal and neoplastic cells.Clin Immunol. 1999 Feb;90(2):157-64. doi: 10.1006/clim.1998.4636. Clin Immunol. 1999. PMID: 10080826 Review.
Cited by
-
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma.J Clin Med. 2022 Nov 6;11(21):6574. doi: 10.3390/jcm11216574. J Clin Med. 2022. PMID: 36362802 Free PMC article. Review.
-
Toxoplasmosis submandibular lymphadenitis: Report of an unusual case with a brief review.J Oral Maxillofac Pathol. 2018 Jan-Apr;22(1):116-120. doi: 10.4103/jomfp.JOMFP_268_17. J Oral Maxillofac Pathol. 2018. PMID: 29731568 Free PMC article.
-
Acute myeloid leukemia targets for bispecific antibodies.Blood Cancer J. 2017 Feb 3;7(2):e522. doi: 10.1038/bcj.2017.2. Blood Cancer J. 2017. PMID: 28157217 Free PMC article. Review.
-
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.JMIR Res Protoc. 2017 Mar 20;6(3):e45. doi: 10.2196/resprot.7289. JMIR Res Protoc. 2017. PMID: 28320689 Free PMC article.
-
Head and Neck Classic Hodgkin, T and NK Lymphomas with Eosinophilia.Head Neck Pathol. 2025 Jan 28;19(1):10. doi: 10.1007/s12105-025-01751-9. Head Neck Pathol. 2025. PMID: 39873807 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical